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Statins, as the most important cholesterol-lowering agents, inhibit the production of blood cholesterol 
by blocking an enzyme called the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-COA) reductase. 
Statins have beneficial effects in some tissues during various injuries. Recent evidence suggests that 
unlike the beneficial effects of statins, administration of high doses of these drugs may increase renal 
impairment, although more research is needed in this regard. Therefore, this study aimed to evaluate 
the possible effect of different doses of statins on the morphology and function of the kidney tubular 
cells.
ABSTRACT
Implication for health policy/practice/research/medical education:
The present study aimed to evaluate the possible effect of different doses of statins on the morphology and function of the kidney tubular 
cells. The results indicated that statins have beneficial effects on renal disorders. However, more attention should be paid to high-dose of 
statins in clinical conditions.
Please cite this paper as: Botshekan S, Yalameha B. Are statins toxic or safe for kidney diseases? An updated mini-review study.  J Nephropathol. 
2020;9(4):e38. DOI: 10.34172/jnp.2020.38.
Introduction
Recently,  cardiovascular diseases are considered as the 
first cause of mortality in industrialized societies and 
developing countries (1). One of the most effective 
prescription drugs lowering serum cholesterol levels are 
statins that were first introduced in 1976. These drugs 
inhibit the activity of a key enzyme named 3-hydroxy-
3-methylglutaryl coenzyme A (HMG-CoA) reductase 
in the pathway of cholesterol synthesis. Statins have 
a substantial influence on the primary and secondary 
prevention of cardiovascular disease, as well as in the 
treatment of ischemic cardiomyopathy. Therefore, it is 
widely recommended for people at risk of heart disease 
(2,3). Furthermore, one of the cardiovascular protective 
capacities of statins is the regulator of the vascular 
function by increasing the activation and expression of 
endothelial nitric oxide synthase (eNOS). The details of 
the mechanism are as follows: statins inhibit the Rho/
ROCK pathway through suppressing isoprenylation and 
translocation of Rho as a small GTPases. In fact, active 
forms of Rho and ROCK diminish phosphorylation and 
mRNA stability of eNOS and subsequently expression 
and activity of eNOS (4). Due to the efficacy and relative 
safety of HMG-CoA reductase inhibitors, prescription of 
statins remains unaffordable over the age of 50 years (5, 
6). Recent studies have suggested that administration of 
high-dose statin to improve cardiovascular complications 
is more effective than that of low-dose. The consumption 
of this drug may be associated with severe side effects such 
as acute renal damage, diabetes, memory impairment, and 
rhabdomyolysis. Thus, more precise studies on the side 
effects of statins are required. Some studies have indicated 
that high-level statin therapy may increase the risk of 
acute kidney injury (AKI), while few studies have been 
conducted on this subject (7-9). Therefore, the present 
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doses of statins on the morphology and function of kidney 
tubular cells.
Materials and Methods 
For this study, we used various databases such as Web of 
Science, PubMed, Embase, Scopus and the directory of 
open access journals (DOAJ). Searching for articles was 
performed using keywords or their equivalents including 
cardiovascular diseases, statin, renal toxicity, statin doses, 
renal failure, and dyslipidemia.
Protective role of statins in renal disorders
Dyslipidemia is considered as one of the known risk 
factors for the development of atherosclerosis as well 
as coronary artery disease, peripheral artery disease, 
and cerebrovascular diseases. Studies have shown that 
disruption in lipoproteins metabolism such as LDL, 
HDL, and triglyceride can accelerate renal dysfunction 
in people with chronic kidney disease (CKD), which 
indicates a positive relationship between dyslipidemia and 
kidney disease (10). 
In fact, the accumulation of lipids in the renal arteries 
triggers the activation of mesenchymal cells and factors 
such as MCP-1 and M-CSF, which results in the use of 
monocytes and the conversion of macrophages into foam 
cells. Then, lipid oxidation can disrupt vascular function 
and expand kidney disorders (11).
Statins are used as effective agents for the treatment 
of lipid disorders. The drug is capable to remove free 
radicals including reactive oxygen species (ROS) in the 
kidneys and also prevents the death of tubular cells by 
the inhibition of nuclear factor-kappa B (NF-κB) and 
mitogen-activated protein kinase (MAPK) signaling 
pathways (6, 12). Statins, in addition to the protective role 
against the rejection of cardiac transplantation, may be 
effective in the kidney and lung transplantation. One of 
the beneficial properties of statin is its pleiotropic effect in 
the treatment of chronic renal failure. It has been proven 
that statins in the kidney have an anti-inflammatory 
role and can affect various signaling pathways including 
inflammation, inhibition of neutrophil accumulation, 
cell death response and proliferative response (13). Statins 
also improve renal disease through potential mechanisms 
such as reducing vascular endothelial disorders and 
decreasing abnormal plasma proteins (14). Studies have 
demonstrated that there is a risk of heart disease in people 
with CKD and statins can be effective in reducing cardiac 
complications by reducing LDL  (15-17). Simvastatin 
administration in CKD patients has been reported to 
decrease the severity of heart muscle damage (18). Hou et 
al found that statin injection in CKD patients undergoing 
dialysis could reduce the risk of cardiovascular disease 
(19). The evaluation of the effect of statin on the levels of 
uric acid and estimated glomerular filtration rate (eGFR) 
and their relationship with patients of coronary heart 
disease and metabolic syndrome showed that long-term 
statin use can increase eGFR and decrease serum uric acid 
level (20). Proteinuria is one of the symptoms of kidney 
dysfunction and an important indicator of kidney disease. 
The result has revealed that statins may reduce proteinuria 
and glomerular damage in renal disorders, although some 
studies have found no relationship on this subject, which 
requires more research (21,22).
Renal ischemia-reperfusion (RIR) is one of the most 
important causes of acute renal injury. RIR can occur 
because of shock, infection, kidney transplantation, and 
vascular surgery (23). 
Previous studies presented that statins possess a 
protective role against RIR injury. Recently, dos Santos 
et al investigated the efficacy of atorvastatin and ischemic 
postconditioning to inhibit RIR injury on 41 norvergic 
male rats. For this purpose, 3.4 mg/d of atorvastatin 
was used for 7 days. Their results suggested that both 
atorvastatin and ischemic postconditioning can alleviate 
renal tissue injury due to IR (24).
Lai et al performed a population-based study on the 
role of two types of statins including atorvastatin and 
rosuvastatin on renal function in type 2 diabetes patients. 
The results demonstrated no significant alteration in 
eGFR level between atorvastatin and rosuvastatin groups. 
However, eGFR level amended significantly in patients 
with CKD in stages 3 to 5 against stages 1 to 2 in both 
groups of high-potency statin consumers (25).
Recent developments regarding statins displayed their 
anti-neoplastic feature that can arrest cell cycle progression 
and inhibit tumor progression and metastasis in different 
cancers including prostate, colorectal, and breast. The 
findings presented that statin as an adjunct treatment 
may improve survival of patients with metastatic renal cell 
carcinoma, however, this supposition requires prospective 
assessment (26,27).
It has been proposed that statins can be lucrative to 
improve one of the sepsis complication including AKI 
(28). In this regard, the recent study of the literature 
designed on the effect of rosuvastatin on AKI due to 
sepsis-associated acute respiratory distress syndrome 
(ARDS) on 745 participants from 2010 to 2013. Their 
findings demonstrated that rosuvastatin therapy has no 
positive effect on de novo AKI or worsening of preexisting 
AKI in patients with ARDS and sepsis (29).
The effects of different doses of statins on the kidney
It has been suggested that despite the beneficial effects 
of statins in reducing heart diseases, these drugs have 
different side effects. Rhabdomyolysis is one of the most 
important complications of statins, leading to lysis of 
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myocytes and the release of compounds such as creatine 
kinase and myoglobin into the plasma (30).
Rhabdomyolysis affects most organs of the body, 
including kidney and heart (cardiovascular disorders), 
pancreas (pancreatitis), damage to the respiratory system, 
and liver (hepatotoxicity) (31,32). In fact, renal disorders 
such as blockage of renal tubules, changing the levels of 
eGFR, and renal toxicity can be due to the myoglobin 
released during rhabdomyolysis (33). Additionally, statins 
alone or together with fibrates can cause myoglobinuria, 
kidney damage, or even death (34).
According to various evidence, the use of high-dose 
statin for the improvement of cardiovascular disease 
complications is more efficient than that of the low- dose 
of statin, while a new study showed that administration 
of high-power statins may cause damage to tubular cells 
and increase the risk of acute renal failure (35). The study 
conducted by Reddy et al on the effect of atorvastatin 
and garlic extract on 56 dyslipidemic rats illustrated 
that the combination of garlic extract and high-dose 
of atorvastatin in comparison with high-dose of garlic 
and low-dose of statin could endanger the health of the 
body. In fact, they concluded that the severity of kidney 
damage in rats receiving high-dose of atorvastatin alone 
or in combination with high levels of garlic is more than 
those of rats receiving low-dose of atorvastatin with high 
concentrations of garlic (36). In addition, Dormuth et al 
reviewed the health care records of patients over 40 years 
of age under statin therapy. They showed that the risk of 
acute renal damage in patients who received high levels 
of statin was more than those who received low-dose of 
statin (37). 
Some studies indicated that there is a relationship 
between nephrotoxicity and the use of statin, while this 
issue is not completely clear and it might be due to an 
abnormality in metabolic function such as the activation 
and fluidity of the membrane chloride channel, and the 
impairment of renal mitochondrial function (38). The data 
were obtained from the evaluation of the dose-dependent 
effects of atorvastatin on rat kidneys for 17 days illustrated 
that there was no significant difference in serum BUN and 
creatinine level in rats treated with doses of 5 mg/kg and 
10  mg/kg of atorvastatin and no abnormality in kidney 
function and nephrotoxicity was observed, although 
doses more than 20 mg/kg increased serum levels of BUN 
and creatinine (39). Statins may cause proteinuria and 
hematuria in individuals treated with 80 mg/kg dose of 
rosuvastatin (40, 41). Therefore, to determine the details 
of the dose-dependent effect of statin, it is necessary to 
conduct studies on a large population with the possibility 
of determining the different dosages of the drug.
Contrast-induced nephropathy (CIN) is recognized 
as the third most prevalent reason for acute renal failure 
that related to intravascular administration of iodinated 
contrast in cardiovascular patients. Commonly, the 
disturbance caused by contrast agents is defined as a 
promotion of serum creatinine more than 25% or ≥0.5 
mg/dL from basal levels within 2-3 days after the use of 
contrast agents (42).
CIN pathogenesis may occur via the induction of 
oxidative stress, the production of ROS, and nephrotoxicity 
due to contrast agents. Additionally, one of the properties 
of statins is antioxidant activity that can reduce ROS 
during the intracellular process (43).
A study was performed on 130 patients undergoing 
angiography including 53 women and 77 men with an 
average age of 54 ± 10 years to evaluate the effect of high-
dose of atorvastatin in the prevention of CIN in the short- 
term. The results showed that high-dose of atorvastatin has 
a beneficial effect on the prevention of CIN in the short-
time. It has been indicated that inflammatory processes 
and oxidative stress play a role in the development of CIN, 
statins can reduce inflammation by improving endothelial 
function and increasing the bioavailability of nitric oxide 
(44,45). 
Additionally, the study on diabetic patients with 
mild-to-moderate CKD performed to measure the role 
of atorvastatin in the improvement of CIN undergoing 
elective percutaneous coronary intervention (PCI). In this 
prospective study, patients randomly and double-blind 
received 80 mg/d of atorvastatin for 48 hours and then 72 
hours and 10 days afterward, GFR and serum creatinine 
surveyed preintervention. The finding revealed that 
80 mg/d dose of atorvastatin declined CIN in diabetic 
patients with CKD undergoing PCI (46).
Zahr et al surveyed the protective effect of atorvastatin 
on a murine model of sickle cell nephropathy by urine 
and flow analysis, assessment of renal histology, GFR 
estimation and the evaluation of cysteine, glutathione 
disulfide, cystine, and glutathione levels in kidney and 
gene expression of NOX4, CYBB, and EDN1 for the 
determination of the oxidative stress level in renal tissue. 
Their results revealed that treatment of humanized sickle 
cell mice with 10 mg/kg/d dose of atorvastatin at 8-10 
weeks diminished albuminuria and also ameliorated urine 
concentrating ability, GFR, glomerular tuft area, oxidative 
stress, and kidney injury (47).
Conclusion
The results of various studies indicate that statins, in 
addition to the cholesterol-lowering effect, have beneficial 
effects in renal disorders. However, taking this drug with 
high-dose can have a deleterious effect on the kidneys, and 
more attention should be paid to high-dose of statins in 
clinical conditions. Therefore, due to the side effects of 
statins, the use of these drugs in patients with various risk 
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factors should be done with caution.
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